What the changes say
- PureCycle added risks regarding its $363.7 million debt load, capital project execution hurdles, and the March 2026 expiration of share lock-up restrictions.
What changed since the prior 10-K
New
- NewRisks Related to PCT’s Status as a Low-Revenue Early Commercial-Stage Company
PCT’s substantial indebtedness, restrictive covenants, and potential inability to obtain additional financing could materially and adversely affect its business, financial condition, results of operations and prospects
As of December 31, 2025, PCT holds $363.7 million in total consolidated indebtedness, including related-party bonds, without material recurring revenue.
- NewRisks Related to PCT’s Status as a Low-Revenue Early Commercial-Stage Company
vulnerability to market conditions, operational challenges, and changes in law or regulations. In addition, PCT’s ability to obtain additional financing for capital expenditures, and other needs may be impaired; by its existing debt and related covenants, as well as by general market conditions
Debt agreements contain restrictive covenants limiting asset sales, debt incurrence, and dividend payments, raising default risks.
- NewRisks Related to PCT’s Operations
If PCT is unable to consistently execute capital investment projects to cost, schedule and operability targets, the Company's reputation, economic viability and ability to raise capital could be impacted, and construction of one or more additional PreP and Purification facilities may be delayed or abandoned
Complex capital projects to build new PreP and Purification facilities face risks of delay, cost overruns, and subsurface site issues.
- NewRisks Related to Regulatory Developments
The use of PureFive® resin in food-grade applications is subject to regulation by the FDA. In order for the PureFive® resin to be used in food-grade applications, PCT may request one or more LNOs from the FDA, as described in Government Regulation - FDA Requirements in Item 1
Using PureFive resin in food-grade applications requires FDA letters of non-objection (LNOs).
- NewRisks Related to PCT’s Common Stock
Future sales of shares of the Company's Common Stock by existing stockholders may depress its stock price
The expiration of the Investor Rights Agreement lock-up on March 17, 2026, will permit the sale of remaining common stock shares, potentially depressing the stock price.
Dropped
- DroppedRisks Related to PCT’s Status as a Low Revenue Early Commercial Stage Company
PCT’s ability to be profitable in the future will depend on PCT’s ability to successfully commercialize PureFive resin products, and any other products PCT may develop in the future, to scale in the United States, Europe and beyond
- DroppedRisks Related to PCT’s Status as a Low Revenue Early Commercial Stage Company
PCT’s outstanding secured and unsecured indebtedness, ability to incur additional debt and the provisions in the agreements governing PCT’s debt, and certain other agreements, could have a material adverse effect on PCT’s business, financial condition, results of operations and prospects
Commercializing PureFive resin to scale in the US and Europe.
- DroppedRisks Related to PCT’s Status as a Low Revenue Early Commercial Stage Company
divert management resources, or otherwise have a material adverse effect on PCT’s business, financial condition, results of operations and prospects
- DroppedRisks Related to PCT’s Operations
Construction of one or more additional pre-processing and purification facilities may be delayed or abandoned
December 31, 2024 total consolidated debt of $346.6 million without revenue.
- DroppedRisks Related to Regulatory Developments
PureFive resin does not meet applicable regulatory requirements in a particular country or at all, then PCT may face reduced market demand in those countries and PCT’s business, financial condition, results of operations and prospects will be adversely affected
- DroppedRisks Related to PCT’s Common Stock
PCT may be unable to obtain additional financing to fund the operations and growth of the business
Legal proceedings, litigation risks, and resulting reputational damage.
Reworded
- 97% rewrittenRisks Related to PCT’s Status as a Low-Revenue Early Commercial-Stage Company
PCT is a low-revenue early commercial-stage company, and may never achieve or sustain profitability, which depends on the successful commercialization and scale-up of PureFive® resin products, and any other products PCT may develop in the future, to scale in the U.S., Europe and beyond
Expanded geographic scope to include Asia and added the need to procure and maintain regulatory approvals for PureFive resin commercialization.
Was: PCT is a low revenue early commercial stage company and may never achieve or sustain profitability
- 71% rewrittenRisks Related to PCT’s Operations
Delays in commissioning and obtaining an independent engineer’s certificate of operational performance at the Ironton Facility or any new project could severely impact PCT’s business, financial condition, results of operations and prospects
Added specific operational hurdles like removing other plastics and additives and sustaining continuous operations at full capacity for the Ironton Facility.
- 68% rewrittenRisks Related to PCT’s Status as a Low-Revenue Early Commercial-Stage Company
PCT faces risks and uncertainties related to litigation, regulatory actions and investigations
Added explicit mention of adverse judgments or settlements resulting in monetary damages or injunctive relief from litigation.
- 64% rewrittenRisks Related to Regulatory Developments
The Company has received LNOs from the FDA that allow the Company's purified product to be used for all food types per the FDA’s COU listed and per all applicable authorizations in the food-contact regulations listed in the 21 CFR (Code of Federal Regulations, Title 21)
Updated to state that the company has received LNOs for all food types and noted evolving FDA expectations impacting further submissions.
Was: The Company’s current LNO from the FDA allows for purified product to be used for all food types per the conditions of use listed and per all applicable authorizations in the food contact regulations listed in the 21 CFR (Code of Federal Regulations, Title 21)
- 62% rewrittenRisks Related to PCT’s Operations
Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect the Company's financial condition and business operations
Identical text retained regarding climate change risks and extreme weather conditions.
Was: Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations
- 51% rewrittenRisks Related to PCT’s Common Stock
Conversion of the Green Convertible Notes and the Convertible Preferred Shares (each as defined below) may dilute the ownership interest of PCT stockholders or may otherwise depress the price of the Company's Common Stock
Added specific figures for the $250 million Green Convertible Senior Notes and Series B Convertible Perpetual Preferred Stock.
Was: Conversion of the Convertible Notes may dilute the ownership interest of PCT stockholders or may otherwise depress the price of our common stock
- 38% rewrittenRisks Related to Human Capital Management
PCT is dependent on management and key personnel, and PCT’s business would suffer if it fails to retain its key personnel and attract additional highly skilled employees
Added specific consequences of key personnel loss, including multi-tasking operational exposures and employee morale decline.
- 38% rewrittenRisks Related to Regulatory Developments
Legislative, regulatory or judicial developments could affect PCT’s business, financial condition, results of operations and prospects
Added specific foreign regulatory authorities including EU EFSA, FASFC, and ASEAN TFDA.
- 36% rewrittenRisks Related to PCT’s Operations
Cybersecurity incidents and the failure to maintain the integrity of PCT’s systems or infrastructure, or those of third parties with which PCT does business, could have a material adverse effect on PCT’s business, financial condition, results of operations and prospects
- 33% rewrittenRisks Related to PCT’s Production of PureFive® Resin
There is no guarantee the Technology is scalable to commercial-scale profitability
- 33% rewrittenRisks Related to PCT’s Common Stock
Certain current and former stockholders of PCT have the right to elect a certain number of directors to PCT’s board of directors (the "Board")
Was: Certain current and former stockholders of PCT have the right to elect a certain number of directors to PCT’s board of directors
- 27% rewrittenRisks Related to PCT’s Status as a Low-Revenue Early Commercial-Stage Company
The License Agreement sets forth certain construction and sales deadlines, which, if missed, could result in a termination or conversion of the license granted under the License Agreement
- 25% rewrittenRisks Related to the Market for PureFive® Resin
Certain of PCT’s offtake agreements are subject to index pricing, and fluctuation in index prices may adversely impact PCT’s financial results
- 22% rewrittenRisks Related to PCT’s Production of PureFive® Resin
PCT’s failure to secure sufficient quantities of waste polypropylene could have a negative impact on PCT’s business, financial condition, results of operations and prospects
Was: PCT’s failure to secure waste polypropylene could have a negative impact on PCT’s business, financial condition, results of operations and prospects
All 28 risk factors
Headings as the filing states them, in filing order.
Risks Related to PCT’s Status as a Low-Revenue Early Commercial-Stage Company
- 01PCT is a low-revenue early commercial-stage company, and may never achieve or sustain profitability, which depends on the successful commercialization and scale-up of PureFive® resin products, and any other products PCT may develop in the future, to scale in the U.S., Europe and beyond97% rewritten
- 02The License Agreement sets forth certain construction and sales deadlines, which, if missed, could result in a termination or conversion of the license granted under the License Agreement27% rewritten
- 03PCT’s substantial indebtedness, restrictive covenants, and potential inability to obtain additional financing could materially and adversely affect its business, financial condition, results of operations and prospectsNew
- 04vulnerability to market conditions, operational challenges, and changes in law or regulations. In addition, PCT’s ability to obtain additional financing for capital expenditures, and other needs may be impaired; by its existing debt and related covenants, as well as by general market conditionsNew
- 05PCT faces risks and uncertainties related to litigation, regulatory actions and investigations68% rewritten
Risks Related to PCT’s Operations
- 06If PCT is unable to consistently execute capital investment projects to cost, schedule and operability targets, the Company's reputation, economic viability and ability to raise capital could be impacted, and construction of one or more additional PreP and Purification facilities may be delayed or abandonedNew
- 07Delays in commissioning and obtaining an independent engineer’s certificate of operational performance at the Ironton Facility or any new project could severely impact PCT’s business, financial condition, results of operations and prospects71% rewritten
- 08PCT currently relies on a single facility for all of its operations, and its business is not diversified
- 09Cybersecurity incidents and the failure to maintain the integrity of PCT’s systems or infrastructure, or those of third parties with which PCT does business, could have a material adverse effect on PCT’s business, financial condition, results of operations and prospects36% rewritten
- 10PCT may be unable to sufficiently protect its proprietary rights and may encounter disputes from time to time relating to its use of the intellectual property of third parties
- 11Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect the Company's financial condition and business operations62% rewritten
- 12PCT may be negatively impacted by volatility in the political and economic environment, which could have an adverse impact on PCT’s business, financial condition, results of operations and prospects
Risks Related to PCT’s Production of PureFive® Resin
- 13There is no guarantee the Technology is scalable to commercial-scale profitability33% rewritten
- 14PCT may not be successful in consummating strategic endeavors for the sale of PureFive® resin products
- 15PCT’s failure to secure sufficient quantities of waste polypropylene could have a negative impact on PCT’s business, financial condition, results of operations and prospects22% rewritten
- 16There is no guarantee the Feed PreP facilities will be viable or achieve the expected efficiencies
- 17There is no guarantee the “Feedstock+” pricing model will be successful
Risks Related to the Market for PureFive® Resin
- 18The market for PureFive® resin is still in the development phase and the acceptance of PureFive® resin by manufacturers and potential customers is not guaranteed
- 19Certain of PCT’s offtake agreements are subject to index pricing, and fluctuation in index prices may adversely impact PCT’s financial results25% rewritten
- 20Delays to direct customer commercial sales may adversely impact PCT's financial results
Risks Related to Regulatory Developments
- 21The use of PureFive® resin in food-grade applications is subject to regulation by the FDA. In order for the PureFive® resin to be used in food-grade applications, PCT may request one or more LNOs from the FDA, as described in Government Regulation - FDA Requirements in Item 1New
- 22The Company has received LNOs from the FDA that allow the Company's purified product to be used for all food types per the FDA’s COU listed and per all applicable authorizations in the food-contact regulations listed in the 21 CFR (Code of Federal Regulations, Title 21)64% rewritten
- 23Legislative, regulatory or judicial developments could affect PCT’s business, financial condition, results of operations and prospects38% rewritten
Risks Related to Human Capital Management
- 24PCT is dependent on management and key personnel, and PCT’s business would suffer if it fails to retain its key personnel and attract additional highly skilled employees38% rewritten
Risks Related to PCT’s Common Stock
- 25Future sales of shares of the Company's Common Stock by existing stockholders may depress its stock priceNew
- 26Certain current and former stockholders of PCT have the right to elect a certain number of directors to PCT’s board of directors (the "Board")33% rewritten
- 27Future offerings of debt or offerings or issuances of equity securities by PCT may adversely affect the market price of PCT’s Common Stock or otherwise dilute all other stockholders
- 28Conversion of the Green Convertible Notes and the Convertible Preferred Shares (each as defined below) may dilute the ownership interest of PCT stockholders or may otherwise depress the price of the Company's Common Stock51% rewritten
Other PureCycle Technologies 10-Ks
- FY2024 10-K risk factors29 risks
PureCycle relies heavily on commercializing its PureFive resin and achieving operational performance at the Ironton facility. The company faces significant financial leverage with $346.6 million in debt and requires additional capital to fund growth. Scaling operations globally involves navigating complex regulatory frameworks like FDA food contact rules and P&G license agreements.
Filed Feb 27, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.